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Bidirectional synaptic plasticity occurs locally at
individual synapses during long-term potentiation
(LTP) or long-term depression (LTD), or globally dur-
ing homeostatic scaling. LTP, LTD, and homeostatic
scaling alter synaptic strength through changes
in postsynaptic AMPA-type glutamate receptors
(AMPARs), suggesting the existence of overlapping
molecular mechanisms. Phosphorylation controls
AMPAR trafficking during LTP/LTD. We addressed
the role of AMPAR phosphorylation during homeo-
static scaling. We observed bidirectional changes
of the levels of phosphorylated GluA1 S845 during
scaling, resulting from a loss of protein kinase A
(PKA) from synapses during scaling down and
enhanced activity of PKA in synapses during scaling
up. Increased phosphorylation of S845 drove scaling
up, while a knockin mutation of S845, or knockdown
of the scaffold AKAP5, blocked scaling up. Finally,
we show that AMPARs scale differentially based on
their phosphorylation status at S845. These results
show that rearrangement in PKA signaling controls
AMPAR phosphorylation and surface targeting dur-
ing homeostatic plasticity.
INTRODUCTION
In response to different types of stimuli, synapses of the CNS
have the ability to change their strength in a bidirectional manner,
a phenomenon known as synaptic plasticity. The most well-
studied forms of synaptic plasticity are long-term potentiation
(LTP) and long-term depression (LTD), collectively referred to
as Hebbian plasticity. LTP and LTD occur at individual synapses,
thus altering the strength of affected synapses relative to nearby
unaffected synapses (Malenka and Bear, 2004). It is widely spec-
ulated that the changes in relative synaptic strength via Hebbian
plasticity form the molecular and cellular basis of learning
and memory. Synapses can also undergo a distinct type of plas-
ticity, known as homeostatic scaling, during which many or all
synapses on a given neuron simultaneously change in synaptic790 Neuron 84, 790–805, November 19, 2014 ª2014 Elsevier Inc.strength in a uniform direction (O’Brien et al., 1998; Turrigiano
et al., 1998). Unlike Hebbian plasticity, homeostatic scaling
alters the strength of all synapses proportionally (Turrigiano
et al., 1998), thus protecting the relative differences in synapse
strengths. However, homeostatic plasticity has also been shown
to occur at individual synapses (Be´ı¨que et al., 2011; Lee et al.,
2010b). By engaging homeostatic scaling, neurons are able to
adjust their own firing rates toward an ideal set point without
disrupting differences in synaptic weights that store information.
In this way, homeostatic scaling may function to maintain
network stability and promote learning andmemory by offsetting
the destabilizing effects of continued LTP or LTD (Turrigiano,
2008). However, at present the relationship between Hebbian
and homeostatic plasticity is not clear (Arendt et al., 2013), and
how scaling is able to proceed without disrupting or erasing
the information from previous Hebbian plasticity events is un-
known. Furthermore, it is unclear how global and local plasticity
simultaneously occur to allow network stability and ongoing
learning and memory formation. LTP, LTD, and homeostatic
scaling each alter synaptic strength in large part by altering the
abundance of AMPA-type glutamate receptors (AMPARs) in
the postsynaptic membrane (Huganir and Nicoll, 2013; Kessels
and Malinow, 2009; Malenka and Bear, 2004; O’Brien et al.,
1998; Shepherd and Huganir, 2007; Turrigiano, 2008). The
shared molecular output of these different plasticity types
strongly suggests that local and global plasticity cannot occur
independently, but rather that the two plasticity types will neces-
sarily have elaborate crosstalk or feedback.
Tetrameric AMPARs aremade from the subunits GluA1–GluA4
andmediate the majority of fast excitatory synaptic transmission
in the CNS. The majority of AMPARs in the hippocampus and
cortex are composed from GluA1/2 and GluA2/3 subunit combi-
nations (Lu et al., 2009; Wenthold et al., 1996). Phosphorylation
of AMPAR cytoplasmic C-terminal tails has been shown to have
a prominent role in controlling AMPAR synaptic targeting as well
as channel properties (Shepherd and Huganir, 2007). During the
induction and maintenance of LTP and LTD, it has been clearly
demonstrated that changes in AMPAR phosphorylation occur
and that these phosphorylation sites regulate LTP and LTD
(Lee et al., 1998, 2000, 2003). In particular, phosphorylation
sites, including the PKA-target GluA1 S845 (Roche et al.,
1996), the CaMKII/PKC-target GluA1 S831 (Mammen et al.,
1997), and the PKC-target GluA2 S880 (Chung et al., 2000),
have been well characterized. PKA-mediated phosphorylation
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A B C Figure 1. Levels of Phosphorylated AMPAR
Change during Homeostatic Scaling
(A) Cortical neurons (13 DIV) were treated 24 or
48 hr with control media (Con), bicuculline (Bic,
20 mM), or tetrodotoxin (TTX, 1 mM), followed by
surface biotinylation and western blot.
(B) Quantification of cell-surface levels of the
AMPAR subunits GluA1, GluA2, or GluA3.
(C) Quantification of total levels of phosphorylated
GluA1 S845 or S831 or GluA2 S880. Values rela-
tive to control, indicated by the dashed line. *p <
0.05, **p < 0.01. Error bars indicate ± SEM. n = 4–6
independent experiments. See also Figure S1.
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insertion and synaptic retention, increase channel open proba-
bility, and facilitate the induction of LTP (Banke et al., 2000;
Ehlers, 2000; Esteban et al., 2003; Lee et al., 2003; Man et al.,
2007; Oh et al., 2006), while dephosphorylation of GluA1 S845
is associated with endocytosis and LTD (Ehlers, 2000; Lee
et al., 2000, 2003; Man et al., 2007). CaMKII-mediated phos-
phorylation of GluA1 S831 increases channel conductance and
regulates LTP (Derkach et al., 1999; Kristensen et al., 2011;
Lee et al., 2000, 2003). Finally, PKC-mediated phosphorylation
of GluA2 S880 disrupts the interaction between GluA2 and
GRIP, allowing for AMPAR endocytosis and LTD (Chung et al.,
2000; Seidenman et al., 2003; Steinberg et al., 2006). Whether
changes in AMPAR phosphorylation also occur during homeo-
static scaling has not been fully addressed, nor is it clear whether
AMPAR phosphorylation is necessary for homeostatic scaling to
occur. It is possible that AMPARs may scale differentially de-
pending on the patterns of phosphorylation that occurred during
earlier LTP or LTD events. In this way AMPAR phosphorylation
may form part of the molecular code to coordinate both global
and local synaptic plasticity.
Levels of protein phosphorylation are governed by the
opposing activities of protein kinases and phosphatases. Scaf-
fold proteins, such as the A-kinase anchor proteins (AKAPs),
can serve as signaling hubs that link second messenger sys-
tems, kinases, and phosphatases with particular targets.
AKAP5 (also called AKAP79 in humans or AKAP150 in rodents)
is a prominent synapse-targeted AKAP that links adenyl cyclase,
protein kinase A (PKA), protein kinase C (PKC), and Ca2+-depen-
dent protein phosphatase calcineurin/PP2B (CaN) with AMPARs
(Colledge et al., 2000; Sanderson and Dell’Acqua, 2011; Tavalin
et al., 2002). In the current study, we show that changes in the
coupling of AMPARs with PKA occur via the scaffold AKAP5.
Reduction in AMPAR-PKA coupling during scaling down results
in a decrease in the level of phosphorylated AMPARs and a
reduced ability to phosphorylate AMPARs upon neuromodulator
stimulation. During scaling up, overall PKA activity is low, butNeuron 84, 790–805, Nactive PKA is concentrated into dendritic
spines, resulting in AMPAR S845 phos-
phorylation and an increased ability to
phosphorylate AMPARs upon neuromo-
dulator stimulation. This reorganization
of PKA signaling requires the scaffold
AKAP5. A GluA1 S845A knockin mutationthat eliminated phosphorylation, abolished scaling up, while
enhancement of S845 phosphorylation can drive scaling up.
Further, we find that phospho-S845 receptors are resistant to
scaling down, showing that AMPARs scale differentially based
on their phosphorylation status. Finally, using a glycine-based
chemical LTP protocol, we show that rearrangements of the
PKA signaling pathway following homeostatic scaling alter the
ability of cortical neurons to express LTP. Thus, we demonstrate
that, like Hebbian plasticity, homeostatic scaling involves
changes in AMPAR phosphorylation, but utilizes distinct mecha-
nisms, and thus interacts with Hebbian synaptic plasticity.
RESULTS
Changes in AMPAR Phosphorylation during
Homeostatic Scaling
We first examined AMPAR phosphorylation during homeostatic
scaling. Cultured rat cortical neurons were treated with bicucul-
line or tetrodotoxin (TTX) for 24 or 48 hr, treatments previously
shown to induce homeostatic scaling down and scaling up,
respectively (O’Brien et al., 1998; Turrigiano et al., 1998). To
monitor the progress of scaling, neurons were surface bio-
tinylated, and surface AMPARs were detected by western blot.
Bicuculline treatment resulted in a loss of surface GluA1,
GluA2, and GluA3 after 48 hr and (to a lesser degree) after
24 hr. TTX treatment resulted in increased surface GluA1 and
GluA2 only after 48 hr of treatment (Figures 1A and 1B). Thus,
bidirectional homeostatic scaling is clearly induced after 48 hr
in our system. Interestingly, TTX treatment did not result in an in-
crease in surfaceGluA3, even after 48 hr, showing that scaling up
likely involves GluA1/2 and not GluA2/3 receptor subunit combi-
nations (Figures 1A and 1B). Using phosphospecific antibodies,
we examined the levels of phospho-S831 and phospho-S845 on
GluA1 and phospho-S880 on GluA2, well-characterized sites
previously shown to be involved in Hebbian plasticity (Shepherd
and Huganir, 2007). Bicuculline treatment for 48 hr resulted in a
significant decrease in AMPA receptor phosphorylation at allovember 19, 2014 ª2014 Elsevier Inc. 791
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Figure 2. Reorganization of Synaptic PKA Signaling during Scaling
(A) Cortical neurons (13–14 DIV) were treated with bicuculline/TTX for 48 hr, and the indicated molecules were examined by western blot (n = 5).
(B) Quantification of (A) (n = 5).
(C) Cortical neurons (13–14 DIV) were treated with bicuculline/TTX for 48 hr followed by 10 nM isoproterenol (Iso) for 5 min.
(D) Changes in pS845 were quantified by western blot. Iso-induced increases in pS845 were reduced by bicuculline and enhanced by TTX treatment
(n = 6).
(legend continued on next page)
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AMPA Receptor Phosphorylation and Homeostatic Scalingthree sites (Figures 1A and 1C), with the phospho-S845 levels
showing the most prominent decrease. TTX treatment for 48 hr
resulted in a significant increase in phospho-S845 levels, but
not phospho-S831 or phospho-S880 levels (Figures 1A and
1C). This pattern of S845 phosphorylation was not observed
following acute (10 min) bicuculline or TTX treatment (Figures
S1A and S1B, available online). Therefore, changes in AMPAR
phosphorylation occur during homeostatic scaling.
Reorganization of PKA Signaling during Homeostatic
Scaling
As the PKA-target GluA1 S845 showed the most prominent
changes in phosphorylation during homeostatic scaling, we
next addressed the molecular basis for changes in AMPAR
phosphorylation by PKA. Following a 48 hr treatment with bicu-
culline or TTX, we first examined protein levels of PKA, calci-
neurin (CaN), AKAP5, and the b2-adrenergic receptor, as these
proteins are all known to regulate synapse targeting of GluA1
and phosphorylation of S845 (Hu et al., 2007; Joiner et al.,
2010; Jurado et al., 2010; Zhang et al., 2013). We observed no
change in the levels of the PKA catalytic subunit or the b2-adren-
ergic receptor following scaling. After bicuculline treatment to
induce scaling down, there were small but significant decreases
in the levels of the catalytic subunit of CaN and AKAP5 (Figures
2A and 2B). Decreased CaNphosphatase upon bicuculline treat-
ment would be expected to result in increasedGluA1 S845 phos-
phorylation, contrary to our observations. On the other hand,
AKAP5 is known to anchor PKA with the GluA1 AMPAR subunit
(Sanderson and Dell’Acqua, 2011). Therefore, the decrease in
AKAP5 protein following bicuculline treatment suggested that a
loss of coupling between PKA and GluA1 may be responsible
for decreased S845 phosphorylation during scaling down.
To address this possibility, we treated neuronswith bicuculline
or TTX for 48 hr to induce scaling and then challenged the neu-
rons for 5 min with isoproterenol (10 nM), a noradrenaline analog
known to cause cyclic AMP (cAMP)/PKA-mediated phosphory-
lation of GluA1 S845 through the b2-adrenergic receptor (Hu
et al., 2007; Joiner et al., 2010). As expected, isoproterenol
challenge resulted in a clear increase in phospho-S845 levels
in previously untreated neurons. Interestingly, phosphorylation
of S845 following isoproterenol challenge was significantly
reduced in neurons pretreated with bicuculline and increased
in neurons pretreated with TTX (Figures 2C and 2D). As the pro-
tein levels of the b2-adrenergic receptor were not altered, we
believe these observations are the result of suppression or
enhancement of PKA activity toward GluA1 during scaling
down or up, respectively. Indeed, this phosphorylation pattern
was not observed at nonsynaptic PKA targets, such as CREB
(S133) or inhibitor protein 1 (I-1, T35), upon isoproterenol treat-
ment (Figures S1C and S1D) or at the PKC target GluA2 S880
upon PKC activation with phorbol ester PMA (Figures S1E and
S1F). In addition, acute treatment with bicuculline or TTX did(E–H) Hippocampal neurons (14 DIV) transfected with GFP and treated with bic
dendritic spines was observed and quantified (F and H) (n = 50–75 spines each fro
but is observed in dendritic spines. Following bicuculline treatment, PKA moves
(I) AKAP5 was immunoprecipitated from bicuculline/TTX-treated cortical neuron
treatment (n = 3). *p < 0.05, **p < 0.01. Error bars indicate ± SEM. See also Figunot affect isoproterenol-induced phosphorylation of S845 (Fig-
ures S1A and S1B). Therefore, not only are the levels of phos-
phorylated GluA1 S845 altered during homeostatic scaling, but
the ability of PKA to phosphorylate GluA1 in response to stimuli
is altered. These results suggest the specific rearrangements of
PKA signaling at the synapse during scaling.
We also examined the cellular distribution and association
of PKA and AKAP5 during homeostatic scaling using immuno-
fluorescence microscopy and coimmunoprecipitation (coIP),
respectively. The PKA catalytic subunit showed prominent den-
dritic shaft targeting (Zhong et al., 2009) but nonetheless could
also be detected in dendritic spines, shown using a GFP cell fill
or overlap with the synapse marker PSD95. We determined a
spine enrichment value by measuring the staining intensity of
PKA in the dendritic spines versus the dendritic shaft. We
observed a significant decrease in the localization of PKA to den-
dritic spines following 48 hr bicuculline treatment but no change
following TTX treatment (Figures 2E and 2F). AKAP5 was more
enriched in dendritic spines, and this distribution was not altered
during homeostatic scaling (Figures 2G and 2H). The removal of
PKA, but not AKAP5, from dendritic spines during scaling down
suggests that the association between the two proteins may be
decreased. Indeed, we detected a decrease in the coimmuno-
precipitation of PKA and AKAP5 following bicuculline treatment
(Figure 2I).
In parallel, we were also interested in the overall level and dis-
tribution of PKA activity during homeostatic scaling. To address
this, we performed western blot on control, bicuculline-, or TTX-
treated samples using an antibody raised against a consensus
PKA phosphosubstrate. We found that the overall western blot
signal was not altered in bicuculline-treated samples compared
to untreated samples but was significantly reduced in TTX-
treated samples (Figures 3A and 3B). No significant changes
were seen under these conditions using a similar PKC phospho-
substrate antibody (Figures 3A and 3B). We confirmed that these
antibodies were phosphospecific (Figure S2). Next, we exam-
ined the dendritic distribution of PKA activity during homeostatic
scaling using a previously developed fluorescence-resonance
energy transfer (FRET) sensor, A-kinase activity reporter
(AKAR4) (Depry et al., 2011; Zhang and Allen, 2007). This re-
porter contains a PKA target site and upon phosphorylation un-
dergoes a conformational shift resulting in an increased FRET
signal. Using this FRET reporter, we found PKA activity distrib-
uted equally in dendritic spines and dendritic shaft in control
neurons. Following bicuculline treatment, there was a significant
reduction in PKA activity in dendritic spines relative to dendritic
shaft. In contrast, following TTX treatment, the activity of PKA
in dendritic spines was greatly increased compared to that in
dendritic shafts (Figures 3C and 3D). Finally, we purified postsyn-
aptic densities (PSD) from bicuculline- or TTX-treated neurons
(Figure 3E) and examined PKA activity in the PSD using
the PKA substrate antibody. Unlike the pattern observed inuculline or TTX. The localization of PKA catalytic subunit (E) or AKAP5 (G) to
m 11–17 neurons. Scale bar, 5 mm. PKA has strong dendritic shaft localization
out of spines.
s (13–14 DIV). Coimmunoprecipitation of PKA is reduced following bicuculline
res S1 and S3.
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Figure 3. Levels and Cellular Distribution of PKA Activity during
Scaling
(A) Cortical neurons (13–14 DIV) were treated with bicuculline/TTX for 48 hr.
Global PKA or PKC activity was assessed by western blot of whole-cell lysates
using pan phosphosubstrate antibodies.
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794 Neuron 84, 790–805, November 19, 2014 ª2014 Elsevier Inc.whole-cell lysate, PKA activity in the PSD was increased
following TTX treatment (Figures 3F and 3G). Furthermore, we
observed that the scaffold AKAP5 showed a significant increase
in PSD association following TTX treatment (Figures 3F and 3H).
As AKAP5 targeting to dendritic spines is not altered during
scaling (Figures 2G and 2H), it is likely that increased AKAP5 in
the PSD is supplied from a perisynaptic pool of AKAP5 mole-
cules. Overall, these findings show that PKA activity is high dur-
ing scaling down, but there is a loss of PKA protein and activity
from dendritic spines and a decrease in PKA phosphorylation
of GluA1. During scaling up, overall PKA activity is low, but active
PKA is enriched in dendritic spines, allowing increased phos-
phorylation of GluA1 S845 (summarized in Figure S3). These
findings further strengthen our hypothesis that PKA signaling,
and the access of PKA to its substrate GluA1, is altered during
homeostatic scaling and also explain why isoproterenol-induced
AMPAR phosphorylation was altered following scaling.
AKAP5 Is Required for Homeostatic Scaling up
Our results point toward a prominent role for AKAP5 in shaping
signaling events toward AMPARs during homeostatic scaling.
To directly address the role of AKAP5, we transfected neurons
with a vector control or with an shRNA against rat AKAP5
(shAKAP5) that effectively reduces its expression (Figure S4A).
In vector-transfected neurons treated with bicuculline/TTX, we
observed the same changes in surface AMPAR subunits and
phosphorylation observed in nontransfected cells in Figure 1
(Figures 4A–4C). Neurons transfected with shAKAP5 showed
reduced levels of AKAP5 protein, but not of the PKA catalytic
subunit. In addition, AKAP5 knockdown caused a significant
reduction in surface levels of all AMPAR subunits and reduced
phosphorylation at GluA1 S845 and S831 and GluA2 S880.
This is consistent with the ability of AKAP5 to anchor both PKA
and PKC (Sanderson and Dell’Acqua, 2011). Further decreases
in AMPAR phosphorylation and surface levels were still
observed in shAKAP5-transfected neurons following bicuculline
treatment, suggesting that knockdown of AKAP5 partly mimics
scaling down. However, increased GluA1 phospho-S845 and
surfaceGluA1 andGluA2 normally observed upon TTX treatment
were completely blocked in AKAP5 knockdown neurons (Figures
4A–4C). Surface GluA1 antibody labeling and fluorescence mi-
croscopy confirmed that AKAP5 knockdown blocked scaling
up and partly mimicked scaling down (Figures 4D and 4E). Basal
levels of surface GluA1 and bidirectional scaling were restored(B) Quantification of pan phosphosubstrate blots indicates a significant
reduction in PKA activity in whole-cell lysate after TTX treatment (n = 6).
(C) PKA activity was visualized using a FRET-based A-kinase activity reporter,
AKAR4, transfected into cortical neurons (13–15 DIV) treated with bicuculline/
TTX for 48 hr. The false color scale is indicated. Scale bar, 5 mm.
(D) FRET spine enrichment value; N = 50–70 spines each from 9–18 neurons.
(E) PSD preparations from cultured cortical neurons. Homogenate (Homo.),
cytosol fraction (S2), membrane fraction (P2), PSD fraction (PSD).
(F) Western blot for PKA phosphosubstrate or AKAP5 in PSD samples from
control, bicuculline-, or TTX-treated neurons.
(G) PKA substrate blot indicates an increase in PKA activity in the PSD
following TTX treatment (n = 4).
(H) AKAP5 in the PSD was significantly increased following TTX treatment (n =
4). *p < 0.05, **p < 0.01. Error bars indicate ± SEM. See also Figures S2 and S3.
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Figure 4. AKAP5 Knockdown Partly Occludes Scaling down and Blocks Scaling up
(A) Cortical neurons (13–14 DIV) electroporated with control vector (pSuper) or shRNA against rat AKAP5 (shAKAP5) and treated with bicuculline/TTX for 48 hr
followed by surface biotinylation and western blot.
(B) Surface levels of GluA1, GluA2, or GluA3 were quantified (n = 5).
(C) Total levels of phosphorylated GluA1 S845 or S831 or GluA2 S880 were quantified (n = 5). Data are normalized and compared statistically to untreated vector-
transfected controls.
(D) Cortical neurons (13–14 DIV) were cotransfected with GFP together with control vector, shAKAP5, or shAKAP5/human myc-tagged AKAP5 (sh+rescue) and
treated with bicuculline/TTX for 48 hr. Surface GluA1 was labeled with an anti-N-terminal antibody followed by immunofluorescence microscopy. GFP (green),
surface GluA1 (magenta). Scale bar, 20 mm; inset, 5 mm.
(E) Surface GluA1 signal from transfected cells was quantified (N = approximately 10 dendrite segments each from 20–35 transfected neurons). Data are
normalized and compared statistically to untreated vector-transfected controls. *p < 0.05, **p < 0.01. Error bars indicate ± SEM. See also Figure S4.
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AMPA Receptor Phosphorylation and Homeostatic Scalingby cotransfection with shRNA-resistant human AKAP5 (Figures
4D and 4E). Together, these results show that AKAP5 is required
for TTX-induced scaling up and that loss of AKAP5 partially
occluded bicuculline-induced scaling down. Further, we found
that, like bicuculline-induced scaling down, AKAP5 knockdown
impaired PKA phosphorylation of GluA1 S845 following isopro-terenol treatment (Figures S4B and S4C), consistent with previ-
ous results (Zhang et al., 2013).
GluA1 Phospho-S845 Is Required for Scaling up
Next, we performed scaling treatments followed by cell-
surface biotinylation and western blot, mini-EPSC recording, orNeuron 84, 790–805, November 19, 2014 ª2014 Elsevier Inc. 795
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Figure 5. S845 of GluA1 Is Required for TTX-Induced Scaling up
(A–F) Mouse cortical neurons (14–15 DIV) cultured from wild-type (WT) or S831A or S845A GluA1 knockin mice were treated for 48 hr with bicuculline/TTX.
(A) Surface biotinylation and western blot.
(legend continued on next page)
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AMPA Receptor Phosphorylation and Homeostatic Scalingimmunofluorescence microscopy using wild-type or phospho-
deficient transgenic knockin mice in which key serine residues
of GluA1 are mutated to alanine (S831A or S845A)(Lee et al.,
2010a). In cultured cortical neurons from wild-type mice treated
with bicuculline or TTX, we observed a bidirectional change in
surface GluA1 and GluA2, as well as phospho-S845 and
decreased surface GluA3 and phospho-S831 and phospho-
S880 in response to bicuculline (Figures 5A and 5B), similar to
rat neurons (Figure 1). Bidirectional scaling of surface GluA1
and GluA2 was normal in S831A mutant neurons, but TTX-
induced scaling up was completely eliminated in the S845A
mutant neurons (Figures 5A and 5B). Bicuculline-induced scaling
down of surface GluA3 was not different between genotypes
(Figures 5A and 5B). Bicuculline or TTX treatment resulted in
changes in total AMPAR expression, in agreement with previous
findings (Anggono et al., 2011), but these alterations in total AM-
PAR expression were not affected by mutation of S831 or S845
(Figure S5A). Using mEPSC recording, we observed a bidirec-
tional change in mini amplitude in response to bicuculline or
TTX in wild-type neurons. TTX treatment resulted in a significant
increase in mini amplitude in S831A neurons, while in the S845A
neurons the TTX increase in mini amplitude was eliminated (Fig-
ures 5C and 5D). Both S831A andS845A neurons showed a clear
trend toward decreased mini amplitude in response to bicucul-
line, but this was not statistically significant (Figures 5C and
5D). No changes were seen in mEPSC frequency or decay ki-
netics (Figures S5B and S5C). Using surface GluA1 immuno-
staining, we observed bidirectional changes in surface GluA1
inWT and S831A neurons in response to bicuculline or TTX treat-
ment, while scaling up was completely blocked in S845A neu-
rons (Figures 5E and 5F). Thus, the S845 phosphorylation site
of GluA1 is required for homeostatic scaling up. There were no
changes in the total or surface levels of GluA1, GluA2, or
GluA3 between wild-type, S831A, and S845A neurons in the
absence of scaling induction (Figures S5D and S5E). Further,
mutation of S831 or S845 did not affect the basal phosphoryla-
tion levels of the other sites (Figures S5D and S5E).
Increasing Phospho-S845 Promotes GluA1 Surface
Targeting and Scaling up
In order to test howmanipulations of phospho-S845would affect
scaling, neurons were treated with bicuculline/TTX in combina-
tion with forskolin/rolipram (FR; 2.5 mM/100 nM, 48 hr) to activate
PKA or FK506 (2.5 mM, 48 hr) to inhibit CaN, manipulations ex-
pected to increase the levels of phospho-S845. FR treatment
increased the phosphorylation of GluA1 S845 as expected for
this PKA target (Figures 6A and 6B). Moreover, FK506 treatment
significantly increased the levels of GluA1 phospho-S845, con-
firming that CaN is a phosphatase that controls basal levels of
phospho-S845 (Colledge et al., 2000; Tavalin et al., 2002) (Fig-(B) Quantification indicates that scaling up is blocked in S845A neurons (n = 7). D
(C) mEPSC recordings from WT, S831A, or S845A cortical neurons following 48
(D) Quantification of mEPSC amplitude (n = 5–11). Data from each genotype are
(E) Surface GluA1 was labeled using an anti-N-terminal antibody under nonperm
5 mm.
(F) Surface GluA1 levels were quantified on 10–15 dendritic segments each from 2
*p < 0.05, **p < 0.01; ns, no statistical significance. Error bars indicate ± SEM. Sures 6A and 6B). Interestingly, under these conditions we found
that FR or FK506 treatment alone resulted in increased surface
targeting of GluA1 that completely occluded the effect of TTX
(Figures 6A and 6B). Bicuculline-induced scaling down in the
presence of FR or FK506 seemed to be reduced compared to bi-
cuculline-only treatment, but it was still clearly occurring (Figures
6A and 6B). Again, we observed that bicuculline treatment alone
caused a loss of phosphorylation at S845. However, when com-
bined with bicuculline, FR treatment prevented the loss of phos-
pho-S845 and maintained this phosphorylation at a high level.
Interestingly, during bicuculline treatment, FK506 did not prevent
the loss of phosphorylation at GluA1 S845, suggesting that the
loss of phospho-S845 is not due to activation of CaN, but likely
from a reduction in PKA activity toward GluA1 (Figures 6A and
6B). Treatment of wild-type mouse neurons with FR resulted in
increased GluA1 surface targeting, but this was not observed
in phospho-deficient GluA1 S845A mouse neurons, indicating
that FR’s effect on GluA1 surface expression was mediated by
S845 phosphorylation (Figures S5F and S5G). Thus, treatments
leading to phosphorylation of GluA1 S845, either kinase activa-
tion or phosphatase inhibition, promote GluA1 surface targeting.
In order to further characterize the effects of PKA activation
during scaling, surface GluA1 was labeled in neurons treated
with bicuculline, TTX, or FR.We again observed that the increase
in surface GluA1 induced by TTX was occluded by FR treatment,
but bicuculline-induced scaling down could still occur (Figures
S6A and S6B). However, when we costained surface GluA1
with the excitatory synapse marker VGlut1, we observed that
FR and TTX treatment had an additive effect in recruitment of
surface GluA1 to synaptic sites (Figures 6C and 6D). Using elec-
trophysiological recordings, we found that treating neurons with
FR or TTX increased mEPSC amplitude similarly, compared to
untreated neurons (Figures 6E and 6F). When FR was combined
with TTX, we observed a further enhancement of mEPSC ampli-
tude (Figures 6E and 6F), consistent with enhanced synaptic
recruitment of surface GluA1. This finding is in agreement with
earlier studies suggesting that PKA activity primarily acts to in-
crease AMPAR surface targeting and that additional signaling
can recruit these receptors into the postsynaptic density (Este-
ban et al., 2003; Oh et al., 2006). Treatment of FR in combination
with bicuculline reduced mEPSC amplitude compared to FR
treatment alone (Figures 6E and 6F). No changes in mEPSC fre-
quency or decay kinetics were observed (Figures S6C and S6D).
Together, these results indicate that elevated PKA activity can
promote synaptic strengthening and scaling up but that scaling
down can still occur.
Phospho-S845 GluA1 Is Resistant to Scaling down
In the previous experiments, we found that under conditions of
high PKA activity, the loss of phospho-S845 during scalingata from each genotype are normalized to untreated controls.
hr of drug treatment.
normalized to untreated controls.
eabilized conditions following 48 hr of drug treatment. Scale bar, 20 mm; inset,
0–24 neurons. Data from each genotype are normalized to untreated controls.
ee also Figure S5.
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Figure 6. PKA Activity Drives Scaling up
(A–F) Cultured cortical neurons (13–14 DIV) were treated for 48 hr with control media or combinations of bicuculline (20 mM), TTX (1 mM), forskolin + rolipram
(FR, 2.5 mM/100 nM), or FK506 (2.5 mM).
(A) Drug treatment was followed by surface biotinylation and western blot.
(B) Quantification of surface GluA1 or total phospho-S845. Treatment with FR or FK506 increased GluA1 surface levels occluding the effects of TTX. FR causes a
high level of S845 phosphorylation that is maintained throughout scaling (n = 6).
(legend continued on next page)
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Figure 7. Phosphorylated S845 AMPARs
Are Resistant to Scaling down
(A–E) Cortical neurons (13–14 DIV) were treated
with bicuculline (20 mM), TTX (1 mM), or forskolin/
rolipram (FR, 2.5 mM/100 nM) for 48 hr.
(A) Surface biotinylation and western blot. Blots
were probed for surface GluA1 and then reprobed
for surface phospho-S845.
(B) Quantification of surface phospho-S845. Sur-
face phospho-S845 receptors are maintained at a
high level in the presence of FR throughout the
scaling process, despite the observation that total
surface GluA1 levels are reduced in the presence
of bicuculline (n = 4).
(C) PSD preparation from drug-treated neurons.
PSD samples were probed for GluA1 and phos-
pho-S845 by western blot.
(D) Phospho-S845 receptors are retained in the
PSD during scaling under conditions of high PKA
activity (FR) (n = 3).
(E) Phospho-S845 receptors were localized by
comparing their distribution to total GluA1 and
VGlut1. Scale bar, 5 mm. Phospho-S845 receptors
are localized to synapses as seen from the triple
colocalization and are maintained at the synapse
in the presence of bicuculline. Note that phospho-
S845 receptors are only visible by immunofluo-
rescence in the presence of FR. *p < 0.05, **p <
0.01; ns, no statistical significance. Error bars
indicate ± SEM. See also Figure S7.
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AMPA Receptor Phosphorylation and Homeostatic Scalingdown was prevented, but a reduction in surface GluA1 still
occurred. This suggests that under certain signaling conditions
phospho-S845 AMPARs may be resistant to scaling down
and that nonphosphorylated receptors may be preferentially
removed. To further test this possibility, we examined the sur-
face and cellular distribution of GluA1 phospho-S845 during ho-
meostatic scaling. Bicuculline-, TTX-, and FR-treated neurons
were biotinylated, and surface GluA1 was visualized by western
blot. Blots were then stripped and reprobed with the anti-phos-
pho-S845 antibody. Following FR and bicuculline treatment,
there was no decrease in phospho-S845 receptors on the cell
surface even while a reduction in overall surface GluA1 was
observed (Figures 7A and 7B), suggesting that phospho-S845
receptors were preferentially retained on the cell surface while
nonphosphorylated receptors were removed. As an alternate
strategy, we prepared PSD samples from bicuculline-, TTX-,
and FR-treated neurons and examined the PSD levels of phos-(C) Following drug treatments, surface GluA1 (magenta) was labeled followed by total VGlut1 (green). Scale
(D) Surface GluA1 fluorescence intensity was quantified only at areas that overlapped with the synapse mar
synaptic surface GluA1 to a degree similar to that of TTX. FR and TTX showed an additive effect.
(E) mEPSC recording from cortical neurons following 48 hr of drug treatment.
(F) Quantification of mEPSC amplitude. FR treatment increased mEPSC amplitude to a degree similar to th
N = 7–15; *p < 0.05, **p < 0.01; ns, no statistical significance. Error bars indicate ± SEM. See also Figure S6
Neuron 84, 790–805, Npho-S845 receptors. Again, we observed
that FR treatment greatly increased
the level of phospho-S845 in the PSD
and that this level was maintained in thepresence of bicuculline even though GluA1 levels in the PSD
were reduced (Figures 7C and 7D).
Next, we examined the cellular distribution of phospho-S845
receptors. Phospho-S845 receptors could be visualized as
punctate structures only when phosphorylation was increased
by FR treatment in wild-type, but not in S845A mutant neurons
(Figure S7). When we compared the distribution of phospho-
S845 punctae in FR-treated neurons to the excitatory synapse
marker VGlut1, we saw a very clear overlap, suggesting that
phospho-S845 receptors are localized at synapses (Figure 7E).
When neurons were also treated with bicuculline or TTX, we
again observed that the phospho-S845 punctae were synaptic
(Figure 7E). Together, these results show that under conditions
of high-PKA activity, scaling down of GluA1-containing AMPARs
can still occur, but phosphorylated receptors remain on the cell
surface and at synapses. Thus, AMPARs scale differentially
based on their phosphorylation status.bar, 5 mm.
ker VGlut1 (n = 24 fields). FR treatment increased
at of TTX. FR and TTX showed an additive effect.
.
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Figure 8. Scaling and Chemical LTP
(A–H) Cortical neurons (13–14 DIV) were treated with bicuculline (20 mM)/TTX (1 mM) for 48 hr, followed by chemical LTP (cLTP) using glycine (Gly; 200 mM; 5 min
treatment, 20 min chase).
(A) Neurons were then surface biotinylated and lysed for western blot.
(B) Quantification of surface GluA1 and phospho-S845 western blots. Glycine treatment in control neurons results in increased surface GluA1 and phospho-S845
levels (n = 5). Increases are blocked by treatment with bicuculline or occluded by treatment with TTX.
(C) Neurons were treated as in (A), followed by fixation and surface GluA1 labeling with an anti-N-terminal antibody. Scale bar, 20 mm; inset, 5 mm.
(D) Surface GluA1 levels were quantified on 10–15 dendritic segments each from 28–32 neurons per condition.
(legend continued on next page)
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Figure 9. Model of Signaling Mechanisms
Affecting AMPA Receptor Phosphorylation
during Scaling, LTP, and LTD
Scaling involves a change in the coupling of basal
PKA with AMPA receptors via AKAP5, resulting in
increased or decreased AMPA receptor phos-
phorylation. LTP and LTD involve the activation
and recruitment of kinases or phosphatases,
respectively, to increase or decrease AMPA re-
ceptor phosphorylation, respectively. Note that
AKAP5 also participates in LTP and LTD.
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Finally, we tested how the rearrangements in PKA signaling dur-
ing scaling influenced LTP. Cortical neurons were first treated
with bicuculline or TTX to induce homeostatic scaling and then
treated with a glycine-based media that has been well estab-
lished to induce a form of chemical LTP (cLTP) (Liao et al.,
2001; Lu et al., 2001). Using cell-surface biotinylation and west-
ern blot, we observed that glycine treatment in control cells
resulted in a significant increase in surface GluA1 as well as
phosphorylation of S845. Increases in surface GluA1 and phos-
pho-S845 were completely blocked in neurons pretreated with
bicuculline or occluded in neurons pretreated with TTX (Figures
8A and 8B). This result was confirmed using cell-surface immu-
nolabeling and fluorescence microscopy (Figures 8C and 8D).
However, we considered that while scaling blocked/occluded
the increase in surface GluA1 by cLTP, preexisting surface re-
ceptors could still become enriched at synapses. To test this
possibility, we isolated PSD samples from scaled/cLTP-treated
neurons and examined the synaptic levels of AMPAR subunits
by western blot. In control neurons, cLTP resulted in a clear in-
crease in PSD-associated GluA1 and GluA2, but not NMDAR
subunit GluN2B (Figures 8E and 8F). Synaptic GluA3 showed a
trend to increase upon cLTP that was not statistically significant.
Interestingly, we saw no change in synaptic AMPAR subunits
upon cLTP in neurons pretreated with bicuculline or TTX (Figures
8E and 8F). As an alternate strategy, we immunolabeled surface
GluA1 followed by staining of the excitatory synapse marker
VGlut1. We then examined surface GluA1 levels only at regions
positive for VGlut1, and we again conclude that there was an in-
crease in synaptic GluA1 in control but not in scaled neurons
(Figures 8G and 8H).
Similarly to bicuculline-induced scaling down, knockdown
of AKAP5 also blocked the effect of glycine on surface GluA1(E) Following scaling and cLTP treatments, cortical neurons were fractionated to obtain PSD samples. PSD
(F) cLTP results in increased levels of synaptic GluA1 and GluA2 in control neurons but not in neurons pre
condition, data are presented as glycine treated relative to untreated, indicated by the dashed line (n = 3).
(G) Surface GluA1 (magenta) and total VGlut1 (green) were labeled following scaling and cLTP. Scale bar, 5
(H) Surface GluA1 fluorescence intensity was quantified only at areas that overlapped with the synapse mar
For each scaling condition, data are presented as glycine treated relative to untreated (n = 35 fields). *p < 0.05,
indicate ± SEM.
Neuron 84, 790–805, Nand phospho-S845 (Figures S8A–S8D).
Importantly, expression of human AKAP5
could rescue glycine-induced increases
in surface GluA1 in AKAP5 knockdown
neurons (Figures S8C and S8D). Thesefindings again demonstrate the importance of GluA1-PKA
coupling via AKAP5 in controlling AMPA receptor phosphory-
llation and surface targeting. Further, these results show that re-
arrangements of the PKA signaling pathway during homeostatic
scaling have important impacts on the ability of cortical neurons
to express LTP.
DISCUSSION
Changes in PKA Signaling during Homeostatic Scaling
Previous studies have shown that changes in phosphorylation
play a key role in controlling AMPAR synaptic targeting during
Hebbian forms of synaptic plasticity (Hu et al., 2007; Lee et al.,
2000, 2003; Seol et al., 2007; Steinberg et al., 2006). In the cur-
rent study, we investigated the role of AMPAR phosphorylation
in homeostatic scaling, a form of global synaptic plasticity. We
were also interested in the possibility that AMPAR phosphoryla-
tion may mediate interactions between local (Hebbian) and
global (homeostatic) plasticity. AMPAR phosphorylation is gov-
erned by the opposing activities of kinases and phosphatases.
The activities of these enzymes toward specific substrates are
coordinated by scaffold proteins, such as AKAP5 in the case
of AMPARs (Sanderson and Dell’Acqua, 2011). Focusing on
three well-characterized phosphorylation sites, we have shown
that indeed the level of phosphorylated AMPARs does change
during homeostatic scaling. In particular, the level of GluA1
phosphorylated at S845 showed bidirectional changes during
homeostatic scaling, and these changes are brought about
through changes in the coupling of PKA and GluA1 via the
signaling scaffold AKAP5 (Figure 9).
During scaling down, PKA becomes uncoupled from the
scaffold protein AKAP5 and exits dendritic spines. Even though
general PKA activity remains high, this reorganization results in amaterial was analyzed by western blot.
treated with bicuculline or TTX. For each scaling
mm.
ker VGlut1.
**p < 0.01. ns, no statistical significance. Error bars
ovember 19, 2014 ª2014 Elsevier Inc. 801
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AMPA Receptor Phosphorylation and Homeostatic Scalingreduced ability of PKA to access its substrate GluA1, leading to a
loss of GluA1 S845 phosphorylation, reduced effectiveness of
noradrenaline, and a block of cLTP. During scaling up, general
PKA activity is low, but remaining active PKA is enriched in den-
dritic spines, where it can promote the phosphorylation of GluA1
S845. This rearrangement results in enhanced effectiveness of
noradrenaline and an occlusion of cLTP. Both AKAP5 and
GluA1 S845 are required for scaling up, and scaling down can
be partially occluded by knocking down AKAP5. A recent study
found that dark-induced scaling up in the visual cortex also
required GluA1 S845 (Goel et al., 2011). Interestingly, both WT
and S845A knockin neurons showed increased expression of
GluA1 after TTX treatment, and yet S845A neurons completely
lacked scaling up of surface or synaptic AMPARs. This finding
suggests that an increase in GluA1 expression levels is not
sufficient to promote scaling without phosphorylation of S845.
The observed changes in GluA1 phospho-S845 during scaling
are consistent with earlier literature showing that phosphoryla-
tion of GluA1 S845 promotes surface targeting and LTP and
that dephosphorylation promotes GluA1 endocytosis and LTD
(Ehlers, 2000; Esteban et al., 2003; Lee et al., 2003; Man et al.,
2007; Oh et al., 2006).
AMPAR Phosphorylation and Global Synaptic Plasticity
One of the defining features of homeostatic scaling is its multi-
plicative nature, the observation that all synapses on a given
neuron seem to be affected to an equal degree. However, the
mechanism for multiplicative scaling remains largely unknown.
A prevailing model of the excitatory synapse postulates that
the PSD contains slots, which can be occupied by trafficking
AMPARs (Huganir and Nicoll, 2013; Kessels and Malinow,
2009). Synaptic AMPARs undergo continuous turnover as re-
ceptors exit the PSD, leaving empty slots behind, and are re-
placed from pools of surface extrasynaptic receptors. A recent
study demonstrated that an increased off rate of PSD-anchored
AMPARs was one key mechanism contributing to synaptic
weakening during homeostatic scaling down (Tatavarty et al.,
2013). This report demonstrated that increased AMPAR off rates
would allow for uniform adjustments to synaptic strength,
enabling multiplicative scaling down (Tatavarty et al., 2013; Tur-
rigiano, 2008). However, scaling up appeared to utilize a different
mechanism (Tatavarty et al., 2013). Dephosphorylation of GluA1
S845 is believed to destabilize AMPARs on the cell surface and
at the synapse (Ehlers, 2000; Lee et al., 2000, 2003; Man et al.,
2007). Uncoupling of AMPARs from PKA favors dephosphoryla-
tion and may form the molecular basis of this observed destabi-
lization of synaptic AMPARs during scaling down. Conversely,
enhanced coupling between PKA and GluA1 via AKAP5 during
scaling up may increase the surface pool of receptors that could
occupy slots in the PSD, and perhaps increase the slot occu-
pancy in a global fashion, enabling multiplicative scaling up.
LTP has a strong destabilizing effect on neuronal networks due
to its feedforward nature, and this is speculated to be offset by
scaling down (Turrigiano, 2008). Another predicted function of
scaling down, yet untested, is to increase synaptic signal-to-
noise ratios (Turrigiano, 2008). In this scenario, naive synapses
would be more affected than previously potentiated synapses.
Either smaller naive synapses could be weakened below a802 Neuron 84, 790–805, November 19, 2014 ª2014 Elsevier Inc.functional threshold or previously potentiated synapses could
be resistant, or even escape scaling down altogether. We have
shown that when PKA is highly active there is an increase in
phosphorylated S845 receptors; during scaling down, these
phosphorylated receptors remain on the cell surface, at the syn-
apse, and within the PSD, despite the overall loss of AMPARs
from these locations. These results indicate that nonphosphory-
lated receptors are preferentially removed and that PKA-phos-
phorylated receptors are resistant to scaling down. It is possible
that potentiated synapses may maintain a pool of active kinases
and a larger pool of resistant phosphorylated AMPARs, consis-
tent with synaptic tagging (Huang et al., 2006; Sajikumar et al.,
2007). Neuromodulators, such as noradrenaline, that regulate
the cAMP/PKA pathway and modulate AMPAR trafficking may
also influence scaling (Hu et al., 2007; Joiner et al., 2010; Seol
et al., 2007). During global scaling down, localized innervation
of neuromodulators could protect certain synapses from scaling.
Therefore, global decreases in kinase-AMPAR coupling, com-
bined with localized PKA signaling during/following LTP or neu-
romodulator release, offer a mechanistic insight into how scaling
down may proceed in a manner sensitive to the previous history
of the synapse and achieve an enhanced signal-to-noise ratio in
neural networks.
Homeostatic Scaling versus LTP/LTD
During LTP, kinases such as PKA and CaMKII are activated/re-
cruited to phosphorylate AMPARs, promoting receptor insertion
and synaptic potentiation (Huganir and Nicoll, 2013; Lee et al.,
2000; Malenka and Bear, 2004). Blocking protein kinases or
removing the AMPAR phosphorylation sites can impair LTP
(Lee et al., 2000, 2003; Malenka and Bear, 2004). LTD involves
the activation or recruitment of phosphatases such as PP1,
PP2A, and CaN, which can dephosphorylate AMPARs, promot-
ing their removal from the synapse (Figure 9) (Huganir and Nicoll,
2013; Lee et al., 1998, 2000; Malenka and Bear, 2004). In our
model, there is no overt activation or deactivation of kinases or
phosphatases during scaling, but rather changes in the ability
of basal activities of these enzymes to access AMPARs through
changes in coupling via AKAP5 (Figure 9). Indeed, overall PKA
activity was even suppressed during scaling up. Furthermore,
inhibition of CaN with FK506 resulted in increased GluA1 S845
phosphorylation, showing that there is basal PKA activity
acting on this site and that this basal PKA activity is balanced
by CaN phosphatase activity. During LTD, AMPAR dephosphor-
ylation and synaptic depression can be blocked by FK506 (Lee
et al., 2000). Loss of AMPAR phosphorylation during scaling
down, however, was not prevented by FK506, suggesting that
CaN phosphatase is not activated during scaling down. There-
fore, our results show that changes in AMPAR phosphorylation
occur during scaling and Hebbian plasticity. However, homeo-
static scaling employs a fundamentally distinct mechanism
(Figure 9).
While homeostatic scaling and Hebbian plasticity have impor-
tant differences in their molecular mechanisms, these plasticity
types share substantial overlap as well. An important step in
the field will be to understand the relationship between local
and global plasticity types. We found that cLTP was occluded
by scaling up or blocked by scaling down, suggesting that
Neuron
AMPA Receptor Phosphorylation and Homeostatic Scalingadjustments to synaptic weights during homeostatic scaling
may come at the cost of the neuron’s capacity for LTP. Loss of
PKA from the synapse during scaling down may explain the
block of LTP. Indeed, knockdown or knockout of AKAP5, which
anchors PKA in the synapse (Tunquist et al., 2008; Weisenhaus
et al., 2010; Zhang et al., 2013), also blocks LTP, mimicking the
effects of scaling down. It has been speculated that scaling
downmay prevent the feedforward effects inherent in LTP (Turri-
giano, 2008). Therefore, it makes physiological sense that LTP
induction (but not maintenance) should be inhibited during
scaling down. The occlusion of LTP by scaling up may be ex-
plained by a ceiling effect. Increased GluA1 surface targeting
and S845 phosphorylation during scaling up cannot be further
enhanced by cLTP.
A recent study has shown that LTP is enhanced in relatively
young hippocampal slices previously treated with TTX to induce
scaling up (Arendt et al., 2013). The authors observed that
scaling up with TTX treatment induced the formation of silent
synapses and that LTP induction unsilenced these synapses, re-
sulting in substantial potentiation (Arendt et al., 2013). Whether
active (AMPAR-containing) synapses also underwent potentia-
tion or were already at a ceiling of synaptic strength was not
clear. Whether LTP is also enhanced or in fact occluded in older
hippocampal slices following scaling up will need to be tested
(Soares et al., 2013). Another possibility is that the relationship
between local and global plasticity may be unique in different
brain regions or developmental stages, dictated by the physio-
logical function of specific neuron types. Homeostatic plasticity
has also been demonstrated at single synapses (Be´ı¨que et al.,
2011; Lee et al., 2010b). The interaction between single synapse
homeostatic plasticity and Hebbian plasticity also requires
further investigation.
In conclusion, we have shown that homeostatic scaling in-
volves significant alterations in the PKA signaling pathway,
with important consequences on AMPAR phosphorylation and
synaptic strength. Further, AMPARs scale differentially based
on their phosphorylation status, which may form the basis of
interactions between local and global plasticity types.EXPERIMENTAL PROCEDURES
Animal Care
All animals were treated in accordance with the Johns Hopkins University
Animal Care and Use Committee Guidelines.
Chemical LTP and Drug Treatment
To induce homeostatic scaling, neuronswere treated (unless otherwise stated)
for 48 hr with bicuculline methobromide (20 mM) or tetrodotoxin (TTX, 1 mM).
For some experiments, these treatments were used in combination with
forskolin/rolipram (2.5 mM/100 nM) or FK506 (2.5 mM). For some experiments,
neurons were treated with isoproterenol (10 nM) or phorbol-myristoyl-acetate
(PMA, 10 nM) for 5 min at the end of the 48 hr scaling treatments or following a
5 min pretreatment with bicuculline or TTX. For chemical LTP experiments,
neurons were first preincubated for 15 min at 37C in chemLTP buffer
(125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 33 mM glucose,
25 mM HEPES [pH 7.4], 20 mM bicuculline, 500 nM TTX, 1 mM strychnine),
followed by glycine treatment for 5 min (chemLTP buffer, 200 mM glycine,
0 magnesium), and then returned to the original buffer (without glycine) for
20 min prior to lysis/fixation. Neurons were used at 13–15 days in vitro (DIV)
for all experiments.Surface Biotinylation
Neurons were rinsed with ice-cold PBS containing 0.1 mM CaCl2 and 1 mM
MgCl2 (pH 8.0) (PBSCM), incubated in PBSCM containing 0.5 mg/ml
Sulfo-NHS-SS-biotin (Thermo Scientific, 30 min, 4C), then rinsed in
PBSCM, and unreacted biotinylation reagent was quenched in PBSCM
containing 20 mM glycine (2 3 7 min, 4C). Cells were lysed in lysis buffer
(PBS containing 50 mM NaF, 5 mM sodium pyrophosphate, 1% NP-40,
0.5% sodium deoxycholate, 0.02% SDS, 1 mM okadaic acid, 1mM
Na3VO4, and protease inhibitor cocktail [Roche]). Protein concentration of
each lysate was quantified using Bradford reagent (Bio-Rad), and equal
amounts of protein were incubated overnight with NeutrAvidin coupled-
agarose beads (Thermo Scientific). Beads were washed three times with
ice-cold lysis buffer, and biotinylated proteins were eluted with 23 SDS
sample buffer. Cell-surface or total proteins were then subjected to SDS-
PAGE and analyzed by western blot.
Immunocytochemistry
For surface AMPA receptor labeling, neurons were fixed for 5 min at room
temperature in PBS containing 4% paraformaldehyde (PFA)/4% sucrose,
rinsed with PBS, blocked with 10% goat serum in PBS for 30 min, and incu-
bated with mouse anti-GluA1 (anti-N terminus) antibodies in PBS with 1%
goat serum (2 hr). Coverslips were washed with PBS. In some experiments,
neurons were permeabilized with 0.1% Triton X-100 followed by labeling
with guinea pig anti-VGlut1 (2 hr). Coverslips were incubated with Alexa
Fluor 568-conjugated goat anti-mouse and Alexa Fluor 647 goat anti-guinea
pig secondary antibodies in PBS containing 1% goat serum for 45 min. Af-
ter final washes with PBS, coverslips were mounted onto glass slides using
Fluoromount-G (Southern Biotech). All steps were performed at room tem-
perature. For all other immunocytochemistry experiments, neurons were
fixed as above for 10 min, followed by PBS rinse and then permeabilized
with 0.1% Triton X-100 in PBS for 10 min. Fixed neurons were then blocked
as above and incubated with primary antibodies in PBS containing 1% goat
serum overnight at 4C. Neurons were rinsed, incubated with fluorescently
labeled secondary antibodies, and mounted onto glass slides as above.
Images were obtained using a 510 laser scanning confocal microscope
(Zeiss).
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